10x Genomics, Inc.
TXG
$27.48
$1.194.53%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 17.76% | 17.22% | 28.10% | 17.28% | 8.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.76% | 17.22% | 28.10% | 17.28% | 8.85% |
| Cost of Revenue | 86.70% | 91.31% | 70.40% | 40.89% | 183.20% |
| Gross Profit | -3.28% | -5.13% | 14.62% | 10.53% | -8.36% |
| SG&A Expenses | 6.84% | 12.28% | 15.34% | 24.90% | 9.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.61% | 21.03% | 18.26% | 19.23% | 21.06% |
| Operating Income | -53.45% | -33.50% | -0.38% | -24.57% | -1,572.21% |
| Income Before Tax | -183.94% | -129.16% | 4.80% | -19.09% | -2.61% |
| Income Tax Expenses | 192.79% | -33.90% | 162.68% | 52.02% | -67.26% |
| Earnings from Continuing Operations | -184.36% | -121.85% | 3.17% | -19.65% | 6.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.36% | -121.85% | 3.17% | -19.65% | 6.69% |
| EBIT | -53.45% | -33.50% | -0.38% | -24.57% | -1,572.21% |
| EBITDA | -55.78% | -30.09% | 5.65% | -28.03% | -366.07% |
| EPS Basic | -175.27% | -115.03% | 5.76% | -16.92% | 9.04% |
| Normalized Basic EPS | -61.65% | -21.89% | 7.37% | -12.31% | -823.61% |
| EPS Diluted | -175.27% | -115.03% | 5.76% | -16.92% | 9.04% |
| Normalized Diluted EPS | -61.65% | -21.89% | 7.37% | -12.31% | -823.61% |
| Average Basic Shares Outstanding | 3.32% | 3.17% | 2.76% | 2.35% | 2.56% |
| Average Diluted Shares Outstanding | 3.32% | 3.17% | 2.76% | 2.35% | 2.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
